| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|
|
maxsyn
Veteran |
30-Oct-2006 17:03
|
|
x 0
x 0 Alert Admin |
target to close above 90 cts |
| Useful To Me Not Useful To Me | |
|
maxsyn
Veteran |
28-Oct-2006 18:35
|
|
x 0
x 0 Alert Admin |
short term support @0.90, testing new resistance @0.92 early next week again. should be able to move for another week if break 0.92 resistance, target @0.955 bought at previous support @0.875 last week |
| Useful To Me Not Useful To Me | |
|
|
|
|
sharemoney
Member |
22-Sep-2006 08:52
|
|
x 0
x 0 Alert Admin |
one of the company staff is attending conference and speak on ..... next week. the counter will go up. time to buy. |
| Useful To Me Not Useful To Me | |
|
singaporegal
Supreme |
15-Sep-2006 10:08
Yells: "Female TA nut" |
|
x 0
x 0 Alert Admin |
Biosensors looks to be on a downtrend. Also, sudden price movement may occur soon. |
| Useful To Me Not Useful To Me | |
|
hikitty
Master |
15-Sep-2006 09:41
|
|
x 0
x 0 Alert Admin |
It seems to be a victim of rotational contra play despite being promising. Promising or potential growth are vague terms, but are without confirmed earnings growth expressed in dollars and cents. Unless one is a trader, it does not make sense to buy this stock at this point of time. Agree? |
| Useful To Me Not Useful To Me | |
|
|
|
|
Nostradamus
Supreme |
14-Sep-2006 23:32
|
|
x 0
x 0 Alert Admin |
This could mean more upside for Biosensors... A study released by the New England Journal of Medicine (NEMJ) found drug-eluting stents are safer for use after heart attacks than older-model, bare-metal stents. The news comes just a week after Boston Scientific said internal research confirmed an increased risk of blood clots with its drug-coated Taxus stent. Drug-coated stents, which are used to keep arteries open after heart surgery, have gained popularity in recent years. Nearly 6m patients worldwide have received coated stents and the market is worth more than US$5b a year. Taxus and Johnson & Johnson's Cypher stent are the market leaders. The new research, which will appear in today's edition of the NEMJ, includes data from two large studies that evaluated the benefits of drug-eluting stents versus bare-metals stents. In a study funded by Johnson & Johnson appearing in the journal, the company's Cypher stent was significantly better at keeping blood flowing through the arteries of a heart attack victim when compared with bare-metal stents. A second independent study involving Boston Scientific's Taxus stent appearing in the journal found no statistical benefit over uncoated stents. An editorial by Frans Van de Werf of the University of Leuven in Belgium cautioned that "it would be dangerous to conclude from these data that one drug-eluting stent is better than the other" because the two brands were not compared in a head-to-head test. The editorial suggests drug-eluting stents are safe and effective for patients after severe heart attacks, but more research is needed on the risk of blood clots before the devices can be recommended for all heart attack patients. Published September 14, 2006 by the Boston Business Journal |
| Useful To Me Not Useful To Me | |
|
Nostradamus
Supreme |
14-Sep-2006 14:54
|
|
x 0
x 0 Alert Admin |
UBS has started coverage with a target price of $1.25 as it expects the company to secure a decent slice of the US$6b market for drug-eluting stents (DES) as soon as it wins regulatory approvals for its DES products. "Biosensors is entering the lucrative DES market where gross margins are over 80% for the established players," UBS said. "Biosensors' flagship 'BioMatrix' stent has a bioresorbable polymer that might be preferred to the durable polymer stents that most players, including industry leaders, offer. We forecast Biosensors to secure about an 8% market share by the year to March 2014," the brokerage said. Securing regulatory approvals, or CE Mark, for its DES products would provide the near-term catalyst for the stock, UBS said. "Comparing the results of trials conducted by Biosensors with results of similar trials conducted by its peers, we believe the company is likely to receive CE Mark approval in the second half of 2006," it added. UBS also said Biosensors may release clinical data from its already concluded Beacon registry over the next few months, "and this could also prove to be a positive catalyst." |
| Useful To Me Not Useful To Me | |
|
knightrider
Elite |
14-Sep-2006 09:23
|
|
x 0
x 0 Alert Admin |
It seems this one is a black horse today ! Cheong already after one director bought in 8 millions share a few day earlier !!! |
| Useful To Me Not Useful To Me | |
|
|
|
|
quino9
Member |
04-Sep-2006 16:53
|
|
x 0
x 0 Alert Admin |
qutoe "Biosensors May Recover 0.5C On Query Response 1350 [Dow Jones] Biosensors (B20.SG) could retrace some of morning's losses after responding to query from SGX; says "although other stent manufacturers were specifically mentioned in the presentation made during the World Congress of Cardiology 2006 conference, there was no mention of the company or its products." Pre-open quotes suggest stock may recover 0.5 Singapore cents in early afternoon trade, with 100,000 bids at 87 cents. Adds its Biomatrix, Axxion drug-eluting stents "do not leave a polymer in the body after the drug is fully eluted," concerns that WCC results highlighted. Most active stock on market, with 31.7 million shares traded before break. Closed off 5.0% at 86.5 cents at midday, having earlier fallen to 81.5 cents. (JEM) " unquote.. |
| Useful To Me Not Useful To Me | |
|
Nostradamus
Supreme |
04-Sep-2006 12:10
|
|
x 0
x 0 Alert Admin |
Nothing new here. A meta analysis of results from past clinical trials of first-generation, drug-coated stents presented at the Congress showed that patients who received coated or "drug-eluting" stents - the tiny tubes used to prop open diseased arteries - had a greater risk of heart attack or death than patients given a bare metal stent. The company, however, said previously that its drug-coated stents cannot cause blood clots as the polymers covering its drug-coated stents biodegrade over time, leaving bare metal stents after they have delivered their medication. Drug-coated stents account for about 40% of its revenues. |
| Useful To Me Not Useful To Me | |
|
Nostradamus
Supreme |
04-Sep-2006 11:12
|
|
x 0
x 0 Alert Admin |
It is sharply lower on fresh concern over the safety of its stents after medical experts at the World Cardiology Congress held in Barcelona over the weekend raised the issue about risks that may accompany drug-coated stents, dealers said. A Swiss-Dutch study presented at the meeting tracked 8,146 patients and found that recipients of drug-coated stents were at increased risk of thrombosis, or blood clots, that can occasionally result in death. |
| Useful To Me Not Useful To Me | |
|
alto26
Member |
04-Sep-2006 11:01
|
|
x 0
x 0 Alert Admin |
opps, that is for biotreat, not biosensor, anyway ,these 2 counters have a rough start today |
| Useful To Me Not Useful To Me | |
|
|
|
|
alto26
Member |
04-Sep-2006 10:42
|
|
x 0
x 0 Alert Admin |
BROKER CALL - Singapore-listed Bio-Treat target cut to 0.71 sgd - Citigroup |
| Useful To Me Not Useful To Me | |
|
alto26
Member |
04-Sep-2006 10:14
|
|
x 0
x 0 Alert Admin |
thks scotty, chk sgx & they have query too ,see below Dear Sir QUERY REGARDING TRADING ACTIVITY We have noted, and draw to your attention, a substantial decrease in the price of your shares today. To ensure a fair and orderly market, please answer each of the following: Question 1: Are you aware of any information not previously announced concerning you (the issuer), your subsidiaries or associated companies which, if known, might explain the trading? - If yes, the information must be announced immediately. Question 2: Are you aware of any other possible explanation for the trading? |
| Useful To Me Not Useful To Me | |
|
scotty
Senior |
04-Sep-2006 10:04
|
|
x 0
x 0 Alert Admin |
SINGAPORE (Dow Jones)--Medical devices maker Biosensors International
Group Ltd. (B20.SG) swung to a loss in the first quarter as product
development expenses outstripped revenue from sales and licensing. Net loss for the three months ended June 30 was $6.7 million compared with a net profit of $758,000 a year earlier, the company said in a statement Thursday. The net loss in the first quarter was 31% lower than the loss of $9.7 million posted in the fourth quarter of the last fiscal year. Revenue from product sales and licensing was outstripped by expenses which included spending on research and development, clinical trials, patent registration, and costs associated with regulatory approvals. Revenue for the quarter was $8.0 million, down 46% from $14.9 million a year earlier when it was boosted by non-recurring licensing revenue, the company said. Biosensors is awaiting regulatory approval for its "BioMatrix" drug-eluting stent to be commercialized in the European Union. Stents are tiny tubes which keep a coronary artery open and deliver drugs to keep scar tissue from forming. The BioMatrix stent includes a biodegradable polymer that may have safety advantages over non-biodegradable polymers. Some cardiologists say polymers could induce inflammation and other complications when left in the artery. Sales for the next 12 months will depend on whether approval is received for the BioMatrix stent, the company said. |
| Useful To Me Not Useful To Me | |
|
scotty
Senior |
04-Sep-2006 09:58
|
|
x 0
x 0 Alert Admin |
falling rapidly... its top active counter now |
| Useful To Me Not Useful To Me | |
|
alto26
Member |
04-Sep-2006 09:11
|
|
x 0
x 0 Alert Admin |
big drop? any news |
| Useful To Me Not Useful To Me | |
|
Nostradamus
Supreme |
12-Aug-2006 21:35
|
|
x 0
x 0 Alert Admin |
Drug-eluting stents (DES) sales of US$3.16m was marginally lower than 4QFY06's US$3.23m. As previously explained by management, the DES industry has become increasingly concerned about safety issues of currently-approved DES products. Consequently, distributors continue to face difficulty in pushing sales further due to a lack of clinical data relating to the Axxion DES. Management's focus continues to be on its flagship BioMatrix DES. With expectations of a CE Mark award in the near future, capex to build up clinical data via two large clinical trials as well as investment into BioMatrix's marketing and distribution infrastructure continue to take top priority. |
| Useful To Me Not Useful To Me | |
|
hikitty
Master |
12-Aug-2006 09:09
|
|
x 0
x 0 Alert Admin |
Biosensors will continue to be volatile for some time as it continues to lose (1Q loss of US$6.7m) because of its continued investment in R&D. Unless one is a trader, prepared to take profit or cut loss, it's better to wait for buying interest and a trend reversal, which sadly are not in sight soon. But, why wait "indefinitely" when there are other quality stocks worth buying? |
| Useful To Me Not Useful To Me | |
|
investor
Senior |
11-Aug-2006 22:05
|
|
x 0
x 0 Alert Admin |
On the 8 Aug 2006, Biosensors, technology partner, Xtent Inc (who is using Biosensors Drug, call Biolimus, and polymer on their stent), has filed for a Nasdaq listing. I think Biosensors probably has some shares in Xtent (not sure how much), but more importantly, in the big scheme of things, this can only augur well for Biosensors, as more and more of its technology is being made known to the US investing public. |
| Useful To Me Not Useful To Me | |